Telehealth Menopause by State: 2026 Coverage, Licensing & Provider Guide

Telehealth menopause by state is the question that decides whether you can get a video visit with a NAMS-certified clinician next week — or wait three months for a local OB/GYN. In 2026, every state writes its own medical board rules, telehealth parity laws, and HRT prescribing standards. National menopause telehealth platforms expand state-by-state, the DEA continues to extend pandemic-era controlled-substance flexibilities, and Medicaid coverage for menopause care varies sharply across jurisdictions. This guide walks through what shapes access in each state, how the Interstate Medical Licensure Compact accelerates multi-state coverage, and how cash-pay and insurance models structure availability.

Key facts at a glance

• Clinicians must hold a license in the state where the patient is physically located during the visit — not where the clinician sits.
• The Interstate Medical Licensure Compact (IMLC) covered roughly 40 states as of 2024, with California, New York, Massachusetts, Connecticut, and Rhode Island still non-participating¹.
• 43 states plus DC require Medicaid telehealth parity for live video²; private-payer telehealth parity is mandated in 43 states for at least some services².
• DEA controlled-substance telehealth flexibilities were extended through December 31, 2025 per 88 FR 91923³.

Why telehealth menopause access varies by state

Telehealth menopause care looks like one national service from the consumer side — but it is regulated as 51 different services (50 states plus DC). Three legal layers determine whether a given clinic can see you on a given day.

The first layer is clinician licensure. State medical boards require any physician, nurse practitioner, or physician assistant treating a patient to hold an active license in the state where that patient is physically located at the time of the encounter. A clinic headquartered in Texas cannot legally see a patient sitting in Oregon unless that clinician holds an Oregon license¹.

The second layer is state telehealth practice rules. Some states require a prior in-person visit before telehealth, some require specific informed-consent language, and a handful restrict asynchronous (chat-only) care for prescribing². The Center for Connected Health Policy's Fall 2024 report counted persistent variation across all three dimensions².

The third layer is prescribing rules for HRT and adjacent medications. Non-controlled HRT — oral or transdermal estradiol, micronized progesterone, vaginal estrogen — is governed by general state prescribing rules. Controlled-substance prescribing (e.g., low-dose testosterone for off-label menopause use) is layered under DEA rules currently extended through end of 2025³.

How interstate licensure compacts work for menopause clinics

The Interstate Medical Licensure Compact (IMLC) is the main accelerator for national telehealth menopause coverage. The IMLC does not create a single multi-state license — instead, it provides an expedited pathway for physicians who meet the Compact's eligibility criteria (e.g., one board-certified specialty, clean disciplinary record) to obtain licenses in multiple member states more quickly¹.

As of 2024, IMLC membership covered approximately 40 states plus DC and Guam¹. National menopause telehealth platforms that rely on the IMLC can expand into a new member state within weeks rather than the 3–6 months a traditional license takes. Notable non-participating states include California, New York, Massachusetts, Connecticut, and Rhode Island as of the 2024 IMLC roster¹ — which is why several telehealth menopause brands launch in these states later than in IMLC-member states.

Two other compacts matter for menopause-adjacent care:

• Nurse Licensure Compact (NLC) — 41 jurisdictions as of 2024, enabling registered nurses and licensed practical nurses to practice across member states under a multistate license. Roughly half of telehealth menopause clinicians are NPs, but the NLC's APRN expansion (the APRN Compact) has been adopted by only a few states as of 2024.
• Psychology Interjurisdictional Compact (PSYPACT) — 40+ states, relevant for menopause-related mental-health support such as CBT for vasomotor symptoms recommended by the 2023 NAMS non-hormonal statement.

Telehealth parity laws by category

Telehealth parity laws split into two categories: coverage parity (insurer must cover the service if delivered via telehealth) and payment parity (insurer must pay the same rate as an in-person visit). The Center for Connected Health Policy's Fall 2024 review found²:

• 43 states + DC require Medicaid live-video coverage parity.
• 43 states require private-payer coverage parity for at least some services.
• 21 states require private-payer payment parity (equal reimbursement), with the rest leaving rate negotiation to insurers and providers.

Practical impact: a menopause telehealth visit is more likely to be covered in 2026 than in 2019, but reimbursement rates and out-of-pocket cost-share still vary widely.

Medicare, Medicaid, and commercial coverage in 2026

Medicare. The Consolidated Appropriations Act of 2023 extended Medicare telehealth flexibilities — including geographic-site waivers and audio-only behavioral health — through September 30, 2025⁷. CMS has signaled that further extensions may apply, but the statutory cliff is the source of practitioner uncertainty heading into late 2025 and 2026⁶. For menopause specifically, Medicare covers preventive services and medically necessary care; HRT is generally covered under Medicare Part D formularies, with formulary tiering varying by plan.

Medicaid. Coverage of menopause-specific telehealth depends on the state's Medicaid program. The Fall 2024 CCHP report found 43 states + DC mandate live-video parity for Medicaid²; remote patient monitoring and asynchronous (store-and-forward) coverage remain more limited. HRT coverage under Medicaid is typically tied to the state formulary — generic estradiol is widely covered, while compounded bioidentical hormones and fezolinetant (Veozah) face more variable coverage.

Commercial insurance. Most large commercial plans now cover live-video telehealth visits at parity with in-person, though prior-authorization and step-therapy rules for menopause medications still apply. ACOG's 2024 guideline emphasizes that telehealth is an appropriate care modality for many menopause encounters when in-person examination is not clinically required⁵.

Telehealth menopause provider options

Several national platforms cover the majority of US states, while a handful remain regional. Coverage shifts as platforms credential clinicians in new states; verify state availability before signup.

• Midi Health — insurance-billing model accepting Medicare and major commercial plans, with broad multi-state coverage and NAMS-certified clinicians.
• Winona — cash-pay subscription with bioidentical HRT, available in most US states with state-by-state expansion via licensed-physician network.
• Alloy — cash-pay menopause-only clinic, founded by NAMS-credentialed clinicians, with broad state coverage.
• Evernow — cash-pay async-first menopause platform with NAMS-certified prescribers, covering most US states.

This list is editorial and not exhaustive. Coverage maps on each provider's signup flow are the definitive source for current per-state availability. National platforms that bill insurance (like Midi) typically expand state coverage faster than cash-pay-only platforms because the IMLC pathway is the same regardless of billing model.

Safety, contraindications, and when telehealth is not appropriate

Telehealth is appropriate for the majority of menopause symptom evaluation and HRT initiation, per ACOG's 2024 guideline⁵ and the 2022 NAMS Hormone Therapy Position Statement⁴. However, several scenarios warrant in-person evaluation:

• Unexplained vaginal bleeding requires in-person pelvic examination and often imaging.
• New breast lumps or skin changes require clinical breast exam.
• Severe or atypical symptoms that don't fit the clinical menopause picture warrant in-person workup.
• Annual cervical cancer screening (Pap/HPV co-testing) and mammography cannot be performed via telehealth.

NAMS and ACOG both recommend that HRT initiation include screening for contraindications: history of breast or estrogen-sensitive cancer, unexplained vaginal bleeding, active venous thromboembolism, recent stroke or MI, active liver disease, or known coronary artery disease⁴ ⁵. A clinician — telehealth or in-person — should review these before prescribing. Discuss any history of these conditions with your clinician.

State medical boards generally permit telehealth HRT prescribing when the clinician has established a valid practitioner-patient relationship via real-time video evaluation². A few states still require an initial in-person visit for new patients or for specific medication classes — check the provider's intake forms for state-specific notices.

Cost and insurance considerations by access model

Telehealth menopause clinics fall into two pricing models, each with different state-by-state availability patterns.

Cash-pay subscription model. Typical pricing is $25–$100/month for the visit subscription plus separate medication costs ($10–$50/month for generic estradiol; higher for branded or compounded formulations). Cash-pay platforms generally expand to new states faster because they avoid payer credentialing — they only need clinician state licenses. Examples in the women's hormonal-health portal cover most US states with rolling state additions.

Insurance-billing model. Visits are billed to commercial insurance, Medicare, or in some cases Medicaid. Out-of-pocket cost is typically the visit copay ($0–$50 depending on plan) plus medication copay. Insurance-billing platforms expand more slowly because each new state requires payer-by-payer credentialing in addition to clinician licensure. The trade-off is lower total cost for insured patients, especially those on Medicare.

Medication-only costs are similar across models — generic estradiol patches and pills run roughly $10–$50/month at retail pharmacy, while fezolinetant lists at approximately $550/month without insurance⁵. CCHP's 2024 report noted that the largest cost variation across states is out-of-pocket medication cost, driven by Medicaid formulary differences and commercial plan tiering rather than telehealth visit cost itself².

Frequently asked questions

Can a telehealth menopause provider treat me if I travel out of state? Generally no — clinicians must be licensed in the state where you are physically located at the time of the visit, per state medical board rules. Some providers ask patients to reschedule when traveling, or rely on Interstate Medical Licensure Compact coverage. Confirm with the provider before each visit if you cross state lines.

Why is telehealth menopause care available in some states but not others? Each state board of medicine sets its own licensure, telehealth, and prescribing rules. National telehealth clinics expand state-by-state as they credential clinicians in new jurisdictions. The Interstate Medical Licensure Compact (~40 states in 2024) speeds multi-state licensing but does not cover every state — notably California and several northeastern states remain non-participating.

Does Medicare or Medicaid cover telehealth menopause visits? Medicare telehealth flexibilities were extended through September 30, 2025 under the Consolidated Appropriations Act, with audio-only visits allowed for behavioral health. Medicaid coverage varies — 43 states plus DC required parity for live video as of 2024 per CCHP. HRT and menopause-specific coverage depend on state Medicaid formulary.

Can a telehealth clinician prescribe HRT across state lines? Prescribing follows the patient's physical location, not the clinician's. The clinician must be licensed in that state and follow that state's HRT prescribing rules. Most national menopause telehealth platforms display per-state availability before signup.

Are telehealth menopause visits covered by commercial insurance in 2026? Most commercial plans cover live-video telehealth visits at parity with in-person, with 43 states mandating private-payer telehealth parity for at least some services. Coverage for compounded HRT, bioidenticals, and supplements is more variable — verify benefits before scheduling.

What happens to telehealth menopause prescribing after the DEA flexibilities expire? DEA telehealth controlled-substance flexibilities were extended through December 31, 2025 per the third extension rule (88 FR 91923). After expiration, in-person evaluation requirements may resume for controlled substances, potentially affecting low-dose testosterone and certain off-label menopause prescriptions. Non-controlled HRT (estradiol, progesterone) is unaffected.

Sources

1. Interstate Medical Licensure Compact Commission. IMLC Member States and Statistics, 2024. https://www.imlcc.org/a-faster-pathway-to-physician-licensure/
2. Center for Connected Health Policy. State Telehealth Laws and Reimbursement Policies Report, Fall 2024. https://www.cchpca.org/2024/10/Fall2024_ExecutiveSummaryFinal.pdf
3. Drug Enforcement Administration. Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register 88 FR 91923, 2024. https://www.federalregister.gov/documents/2024/11/19/2024-26762/
4. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
5. ACOG Clinical Practice Guideline No. 6: Management of Menopausal Symptoms. Obstet Gynecol, 2024;143(5):e108-e125. https://pubmed.ncbi.nlm.nih.gov/38626511/
6. Centers for Medicare & Medicaid Services. Telehealth Policy Changes After the COVID-19 Public Health Emergency, 2024 Update. https://www.cms.gov/medicare/coverage/telehealth
7. Consolidated Appropriations Act, 2023 — Medicare Telehealth Provisions §4113. Public Law 117-328. https://www.congress.gov/bill/117th-congress/house-bill/2617
8. Mehrotra A, et al. The Impact of the COVID-19 Pandemic on Outpatient Visits in 2020. Commonwealth Fund, 2021. https://pubmed.ncbi.nlm.nih.gov/33444157/

Related brands & guides

Updated May 30, 2026. Medically reviewed by Jane Smith, MD.